Delivery Order SPE2DB22D3010-SPE2DB25FP2ZR
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,590.58 to AmerisourceBergen Drug Corp for the supply of Ofev 150 mg capsules (60-count) on July 22, 2025, with completion scheduled for August 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,590.58 to AmerisourceBergen Drug Corp for 60 capsules of Ofev 150 mg on July 25, 2025, with an ultimate completion date of August 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be performed from the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ofev 150 mg capsules (60-count units) with a ceiling value of $8,590.58. This firm fixed-price delivery order, which is expected to be completed by August 13, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, and...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of OFEV 150 mg capsules (60-count units) under a firm fixed-price arrangement. The contract, valued at $8,590.58, was competitively awarded without any set-aside designation and carries an ultimate completion date of August 15, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery from its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,771.74 to AmerisourceBergen Drug Corp for the supply of OFEV (nintedanib) 150 mg capsules in quantities of 60 units. This is a firm fixed price delivery order with an ultimate completion date of August 14, 2025, and represents a non-set-aside competitive award. The work will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,590.58 to AmerisourceBergen Drug Corp for OFEV (nintedanib) 150 mg capsules (60-count units) on July 18, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-set-aside award, indicating it was competitively procured. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action, this delivery order is...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The $7,905.56 contract is for the delivery of OFEV 150 MG CAPSULE 60S, a specialty pharmaceutical product, with a performance period through April 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to...
- The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a major pharmaceutical distributor, a $7,905.56 firm fixed price delivery order contract (SPE2DB22D2206|SPE2DB24FJP66) for the supply of OFEV 150 MG CAPSULE 60S. This contract has an ultimate completion date of August 23, 2024. Amerisourcebergen, through its Corporate Office division, will fulfill this order to support the medical needs of the U.S. federal government, which includes military treatment facilities and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ofev (nintedanib) 150 mg capsules in quantities of 60 units. This is a firm fixed-price delivery order with a ceiling value of $8,590.58 and an ultimate completion date of August 8, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The U.S. government's Defense Logistics Agency (DLA) Troop Support Medical awarded a delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide Ofev 150 mg capsules. The $23,716.68 firm fixed price contract has an ultimate completion date of April 2, 2024 and does not have a set-aside designation. AmerisourceBergen Drug Corp, a for-profit organization, serves as the prime contractor to supply pharmaceuticals and medical supplies to support...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP2ZRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Ofev 150 mg capsules (60-count units) valued at $8,590.58 under a firm fixed price arrangement. The contract was competitively awarded without a set-aside designation and is scheduled for completion by August 11, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle running through December 2026. As a critical vendor for federal medical procurement, AmerisourceBergen Drug Corp supplies a comprehensive portfolio of pharmaceuticals and medical supplies to support military and veteran healthcare systems. Ofev (nintedanib) is a specialty medication used in the treatment of progressive fibrosing interstitial lung diseases, reflecting the company's role in furnishing specialized medical commodities across multiple therapeutic domains. This transaction demonstrates the company's capability to meet federal procurement requirements through the DLA's pharmaceutical supply chain, serving customers including the Defense Health Agency and U.S. Coast Guard through flexible contract vehicles designed to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 7/21/25 |